A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Adavosertib (Primary)
- Indications Glioblastoma
- Focus Pharmacokinetics
- 09 Dec 2020 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.